Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Keisuke Hamasaki"'
Autor:
Yuki Minayoshi, Hitoshi Maeda, Keisuke Hamasaki, Taisei Nagasaki, Mei Takano, Ryo Fukuda, Yuki Mizuta, Motohiko Tanaka, Yutaka Sasaki, Masaki Otagiri, Hiroshi Watanabe, Toru Maruyama
Publikováno v:
Pharmaceuticals, Vol 17, Iss 2, p 260 (2024)
Although a lot of effort has been put into creating drugs and combination therapies against chronic hepatitis, no effective treatment has been established. Type-I interferon is a promising therapeutic for chronic hepatitis due to its excellent anti-i
Externí odkaz:
https://doaj.org/article/fac402db87d545768a0dbbc433cc2f77
Autor:
Yuki Minayoshi, Hitoshi Maeda, Hiroki Yanagisawa, Keisuke Hamasaki, Yuki Mizuta, Kento Nishida, Ryo Kinoshita, Yuki Enoki, Tadasi Imafuku, Victor Tuan Giam Chuang, Tomoaki Koga, Yukio Fujiwara, Motohiro Takeya, Kayoko Sonoda, Tomohiko Wakayama, Kazuaki Taguchi, Yu Ishima, Tatsuhiro Ishida, Yasuko Iwakiri, Motohiko Tanaka, Yutaka Sasaki, Hiroshi Watanabe, Masaki Otagiri, Toru Maruyama
Publikováno v:
Drug Delivery, Vol 25, Iss 1, Pp 1055-1065 (2018)
Because of its multifaceted anti-inflammatory and immunomodulatory effects, delivering type-I interferon to Kupffer cells has the potential to function as a novel type of therapy for the treatment of various types of hepatitis. We report herein on th
Externí odkaz:
https://doaj.org/article/981d4d2a40bb4e628b4202b2d6fe85f8
Publikováno v:
In Hepatology 2001 34(4) Part 2:A311-A311
Publikováno v:
In Hepatology 2001 34(4) Part 2:A176-A176
Publikováno v:
Nihon Reoroji Gakkaishi. 48:153-160
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07966ec473097e4160553bd7468b7610
https://doi.org/10.1678/rheology.48.153
https://doi.org/10.1678/rheology.48.153
Autor:
Hiroshi Watanabe, Hitoshi Maeda, Ryo Kinoshita, Kento Nishida, Shiroh Futaki, Tatsuhiro Ishida, Victor Tuan Giam Chuang, Masaki Otagiri, Shota Ichimizu, Taro Shimizu, Yu Ishima, Komei Ikegami, Toru Maruyama, Hiroshi Katsuki, Keisuke Hamasaki, Takahiro Seki
Publikováno v:
Journal of Controlled Release. 304:156-163
We recently developed a cell-penetrating drug carrier composed of albumin (HSA) combined with palmitoyl-cyclic-(D-Arg)12. While it is possible that the palmitoyl-cyclic-(D-Arg)12/HSA enters the cell mainly via macropinocytosis, the mechanism responsi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69afa16e12ffb7fb170fd4a21c4e0a33
https://doi.org/10.1016/j.jconrel.2019.05.015
https://doi.org/10.1016/j.jconrel.2019.05.015
Autor:
Naota Taura, Tatsuki Ichikawa, Hisamitsu Miyaaki, Yoshiko Kadokawa, Takuya Tsutsumi, Shotaro Tsuruta, Yuji Kato, Osami Inoue, Noboru Kinoshita, Kazuo Ohba, Hiroyuki Kato, Kazuyuki Ohata, Junichi Masuda, Keisuke Hamasaki, Hiroshi Yatsuhashi, Kazuhiko Nakao
Publikováno v:
Gastroenterology Research and Practice, Vol 2012 (2012)
Background. HCV infection is associated with lipid disorders because this virus utilizes the host lipid metabolism to sustain its life cycle. Several studies have indicated that higher concentrations of serum cholesterol and LDL before treatment are
Externí odkaz:
https://doaj.org/article/b3efbb25cd7b4a9583fb043a98042817
Autor:
Yuka Nakamura, Akihiko Kuniyasu, Yu Ishima, Ryota Tanaka, Ryo Kinoshita, Yuki Enoki, Yoshihiro Kobashigawa, Shiro Futaki, Hitoshi Maeda, Kento Nishida, Keisuke Hamasaki, Hiroshi Morioka, Shota Ichimizu, Masaki Otagiri, Toru Maruyama, Victor Tuan Giam Chuang, Hiroshi Watanabe
Publikováno v:
Journal of Controlled Release. 277:23-34
Human serum albumin (HSA) is a superior carrier for delivering extracellular drugs. However, the development of a cell-penetrating HSA remains a great challenge due to its low membrane permeability. We report herein on the design of a series of palmi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11c6e8034ba9c81c2cddb5ed6b6dac88
https://doi.org/10.1016/j.jconrel.2018.02.037
https://doi.org/10.1016/j.jconrel.2018.02.037
Autor:
Yutaka Sasaki, Motohiro Takeya, Yuki Mizuta, Tomohiko Wakayama, Kayoko Sonoda, Hiroki Yanagisawa, Yasuko Iwakiri, Yuki Minayoshi, Yuki Enoki, Toru Maruyama, Masaki Otagiri, Yu Ishima, Kento Nishida, Tatsuhiro Ishida, Hiroshi Watanabe, Ryo Kinoshita, Motohiko Tanaka, Victor Tuan Giam Chuang, Kazuaki Taguchi, Tadasi Imafuku, Tomoaki Koga, Keisuke Hamasaki, Yukio Fujiwara, Hitoshi Maeda
Publikováno v:
Drug Delivery, Vol 25, Iss 1, Pp 1055-1065 (2018)
Drug Delivery
Drug Delivery
Because of its multifaceted anti-inflammatory and immunomodulatory effects, delivering type-I interferon to Kupffer cells has the potential to function as a novel type of therapy for the treatment of various types of hepatitis. We report herein on th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a2921a127e2d566520651dbe4f80403
https://doi.org/10.1080/10717544.2018.1464083
https://doi.org/10.1080/10717544.2018.1464083
Autor:
Takuya Tsutsumi, Tatsuki Ichikawa, Jun-ichi Masuda, Shotaro Tsuruta, Kazuhiko Nakao, Keisuke Hamasaki, Noboru Kinoshita, Yuji Kato, Kazuo Ohba, Hiroshi Yatsuhashi, Kazuyuki Ohata, Hisamitsu Miyaaki, Osami Inoue, Hiroyuki Kato, Naota Taura, Yoshiko Kadokawa
Publikováno v:
Gastroenterology Research and Practice
Gastroenterology Research and Practice, Vol 2012 (2012)
Gastroenterology Research and Practice, Vol 2012 (2012)
Background. HCV infection is associated with lipid disorders because this virus utilizes the host lipid metabolism to sustain its life cycle. Several studies have indicated that higher concentrations of serum cholesterol and LDL before treatment are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d1c290033f582575a43c988df0ad8e0
http://hdl.handle.net/10069/31110
http://hdl.handle.net/10069/31110